APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetic Testing For Neurological Disorders

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Genetic Testing For Neurological Disorders Market Analysis and Forecast 2026-2032

28 December 2025195 pages

Choose your research edition.

Industry ResearchGenetic Testing For Neurological Disorders Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Testing For Neurological Disorders Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Genetic Testing For Neurological Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Testing For Neurological Disorders Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Testing For Neurological Disorders Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Genetic Testing For Neurological Disorders market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Genetic Testing For Neurological Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Genetic Testing For Neurological Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Genetic Testing For Neurological Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Genetic Testing For Neurological Disorders is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Genetic Testing For Neurological Disorders include Illumina, CENTOGENE, Victorian Clinical Genetics Services, PacBio, Mayo Clinic, Quest Diagnostics, MedGenome Labs, GeneDx and Connecticut Children's, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Genetic Testing For Neurological Disorders, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Genetic Testing For Neurological Disorders, also provides the revenue of main regions and countries. Of the upcoming market potential for Genetic Testing For Neurological Disorders, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Genetic Testing For Neurological Disorders revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Genetic Testing For Neurological Disorders market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Genetic Testing For Neurological Disorders revenue, projected growth trends, production technology, application and end-user industry.

Genetic Testing For Neurological Disorders Segment by Company

Illumina

CENTOGENE

Victorian Clinical Genetics Services

PacBio

Mayo Clinic

Quest Diagnostics

MedGenome Labs

GeneDx

Connecticut Children's

Labcorp (Invitae/MNG Laboratories)

Genetic Testing For Neurological Disorders Segment by Type

Exome Sequencing

Whole Genome Sequencing

RNA Sequencing

General DNA Testing

Genetic Testing For Neurological Disorders Segment by Application

Hospitals

Specialty Clinics

Diagnostics Laboratories

Genetic Testing For Neurological Disorders Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Testing For Neurological Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Testing For Neurological Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Testing For Neurological Disorders.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Genetic Testing For Neurological Disorders in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Genetic Testing For Neurological Disorders company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genetic Testing For Neurological Disorders revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Genetic Testing For Neurological Disorders Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exome Sequencing Major Player Table 3. Whole Genome Sequencing Major Player Table 4. RNA Sequencing Major Player Table 5. General DNA Testing Major Player Table 6. Global Genetic Testing For Neurological Disorders Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Player Table 8. Specialty Clinics Major Player Table 9. Diagnostics Laboratories Major Player Table 10. Genetic Testing For Neurological Disorders Industry Trends Table 11. Genetic Testing For Neurological Disorders Industry Drivers Table 12. Genetic Testing For Neurological Disorders Industry Opportunities and Challenges Table 13. Genetic Testing For Neurological Disorders Industry Restraints Table 14. Global Genetic Testing For Neurological Disorders Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Genetic Testing For Neurological Disorders Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Genetic Testing For Neurological Disorders Market Share by Region (2021-2026) Table 17. Global Genetic Testing For Neurological Disorders Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Genetic Testing For Neurological Disorders Market Share by Region (2027-2032) Table 19. Global Genetic Testing For Neurological Disorders Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Genetic Testing For Neurological Disorders Revenue Market Share by Players (2021-2026) Table 21. Global Genetic Testing For Neurological Disorders Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Genetic Testing For Neurological Disorders Key Players Headquarters & Area Served Table 23. Global Genetic Testing For Neurological Disorders Players, Product Type & Application Table 24. Global Genetic Testing For Neurological Disorders Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Genetic Testing For Neurological Disorders by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Genetic Testing For Neurological Disorders Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Genetic Testing For Neurological Disorders Revenue Market Share by Type (2021-2026) Table 31. Global Genetic Testing For Neurological Disorders Revenue Market Share by Type (2027-2032) Table 32. Global Genetic Testing For Neurological Disorders Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Genetic Testing For Neurological Disorders Revenue Market Share by Application (2021-2026) Table 36. Global Genetic Testing For Neurological Disorders Revenue Market Share by Application (2027-2032) Table 37. Illumina Company Information Table 38. Illumina Business Overview Table 39. Illumina Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Illumina Genetic Testing For Neurological Disorders Product Portfolio Table 41. Illumina Recent Development Table 42. CENTOGENE Company Information Table 43. CENTOGENE Business Overview Table 44. CENTOGENE Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. CENTOGENE Genetic Testing For Neurological Disorders Product Portfolio Table 46. CENTOGENE Recent Development Table 47. Victorian Clinical Genetics Services Company Information Table 48. Victorian Clinical Genetics Services Business Overview Table 49. Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Product Portfolio Table 51. Victorian Clinical Genetics Services Recent Development Table 52. PacBio Company Information Table 53. PacBio Business Overview Table 54. PacBio Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. PacBio Genetic Testing For Neurological Disorders Product Portfolio Table 56. PacBio Recent Development Table 57. Mayo Clinic Company Information Table 58. Mayo Clinic Business Overview Table 59. Mayo Clinic Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Mayo Clinic Genetic Testing For Neurological Disorders Product Portfolio Table 61. Mayo Clinic Recent Development Table 62. Quest Diagnostics Company Information Table 63. Quest Diagnostics Business Overview Table 64. Quest Diagnostics Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Quest Diagnostics Genetic Testing For Neurological Disorders Product Portfolio Table 66. Quest Diagnostics Recent Development Table 67. MedGenome Labs Company Information Table 68. MedGenome Labs Business Overview Table 69. MedGenome Labs Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. MedGenome Labs Genetic Testing For Neurological Disorders Product Portfolio Table 71. MedGenome Labs Recent Development Table 72. GeneDx Company Information Table 73. GeneDx Business Overview Table 74. GeneDx Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. GeneDx Genetic Testing For Neurological Disorders Product Portfolio Table 76. GeneDx Recent Development Table 77. Connecticut Children's Company Information Table 78. Connecticut Children's Business Overview Table 79. Connecticut Children's Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Connecticut Children's Genetic Testing For Neurological Disorders Product Portfolio Table 81. Connecticut Children's Recent Development Table 82. Labcorp (Invitae/MNG Laboratories) Company Information Table 83. Labcorp (Invitae/MNG Laboratories) Business Overview Table 84. Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Product Portfolio Table 86. Labcorp (Invitae/MNG Laboratories) Recent Development Table 87. North America Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Genetic Testing For Neurological Disorders Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Genetic Testing For Neurological Disorders Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Genetic Testing For Neurological Disorders Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Genetic Testing For Neurological Disorders Revenue by Country (US$ Million) & (2027-2032) Table 101. China Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 102. China Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 103. China Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 104. China Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Genetic Testing For Neurological Disorders Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Genetic Testing For Neurological Disorders Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Genetic Testing For Neurological Disorders Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Genetic Testing For Neurological Disorders Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Genetic Testing For Neurological Disorders Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Genetic Testing For Neurological Disorders Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Genetic Testing For Neurological Disorders Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Genetic Testing For Neurological Disorders Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Genetic Testing For Neurological Disorders Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Genetic Testing For Neurological Disorders Image Figure 2. Global Genetic Testing For Neurological Disorders Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Testing For Neurological Disorders Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exome Sequencing Image Figure 5. Whole Genome Sequencing Image Figure 6. RNA Sequencing Image Figure 7. General DNA Testing Image Figure 8. Global Genetic Testing For Neurological Disorders Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Genetic Testing For Neurological Disorders Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Specialty Clinics Image Figure 12. Diagnostics Laboratories Image Figure 13. Global Genetic Testing For Neurological Disorders Market Size (US$ Million) & (2021-2032) Figure 14. Global Genetic Testing For Neurological Disorders Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Genetic Testing For Neurological Disorders Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Genetic Testing For Neurological Disorders Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Genetic Testing For Neurological Disorders Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Genetic Testing For Neurological Disorders Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Genetic Testing For Neurological Disorders Revenue Market Share by Type (2021-2032) Figure 21. Global Genetic Testing For Neurological Disorders Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Genetic Testing For Neurological Disorders Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Genetic Testing For Neurological Disorders Revenue Market Share by Application (2021-2032) Figure 24. North America Genetic Testing For Neurological Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032) Figure 26. North America Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032) Figure 27. North America Genetic Testing For Neurological Disorders Revenue Share by Country (2021-2032) Figure 28. United States Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Genetic Testing For Neurological Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032) Figure 33. Europe Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032) Figure 34. Europe Genetic Testing For Neurological Disorders Revenue Share by Country (2021-2032) Figure 35. Germany Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Genetic Testing For Neurological Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032) Figure 45. China Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032) Figure 46. Asia Genetic Testing For Neurological Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032) Figure 48. Asia Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032) Figure 49. Asia Genetic Testing For Neurological Disorders Revenue Share by Region (2021-2032) Figure 50. Japan Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Genetic Testing For Neurological Disorders Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032) Figure 58. SAMEA Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032) Figure 59. SAMEA Genetic Testing For Neurological Disorders Revenue Share by Country (2021-2032) Figure 60. Brazil Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Genetic Testing For Neurological Disorders Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Exome Sequencing
  • Whole Genome Sequencing
  • RNA Sequencing
  • General DNA Testing
Applications
  • Hospitals
  • Specialty Clinics
  • Diagnostics Laboratories
Companies covered
  • Illumina
  • CENTOGENE
  • Victorian Clinical Genetics Services
  • PacBio
  • Mayo Clinic
  • Quest Diagnostics
  • MedGenome Labs
  • GeneDx
  • Connecticut Children's
  • Labcorp (Invitae/MNG Laboratories)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Genetic Testing For Neurological Disorders Market by Type
  3. 1.2.1 Global Genetic Testing For Neurological Disorders Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exome Sequencing
  5. 1.2.3 Whole Genome Sequencing
  6. 1.2.4 RNA Sequencing
  7. 1.2.5 General DNA Testing
  8. 1.3 Genetic Testing For Neurological Disorders Market by Application
  9. 1.3.1 Global Genetic Testing For Neurological Disorders Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Specialty Clinics
  12. 1.3.4 Diagnostics Laboratories
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Genetic Testing For Neurological Disorders Market Dynamics
  1. 2.1 Genetic Testing For Neurological Disorders Industry Trends
  2. 2.2 Genetic Testing For Neurological Disorders Industry Drivers
  3. 2.3 Genetic Testing For Neurological Disorders Industry Opportunities and Challenges
  4. 2.4 Genetic Testing For Neurological Disorders Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Genetic Testing For Neurological Disorders Market Perspective (2021-2032)
  2. 3.2 Global Genetic Testing For Neurological Disorders Growth Trends by Region
  3. 3.2.1 Global Genetic Testing For Neurological Disorders Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Genetic Testing For Neurological Disorders Market Size by Region (2021-2026)
  5. 3.2.3 Global Genetic Testing For Neurological Disorders Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Genetic Testing For Neurological Disorders Revenue by Players
  2. 4.1.1 Global Genetic Testing For Neurological Disorders Revenue by Players (2021-2026)
  3. 4.1.2 Global Genetic Testing For Neurological Disorders Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Genetic Testing For Neurological Disorders Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Genetic Testing For Neurological Disorders Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Genetic Testing For Neurological Disorders Key Players Headquarters & Area Served
  7. 4.4 Global Genetic Testing For Neurological Disorders Players, Product Type & Application
  8. 4.5 Global Genetic Testing For Neurological Disorders Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Genetic Testing For Neurological Disorders Market CR5 and HHI
  11. 4.6.3 2025 Genetic Testing For Neurological Disorders Tier 1, Tier 2, and Tier 3
5 Genetic Testing For Neurological Disorders Market Size by Type
  1. 5.1 Global Genetic Testing For Neurological Disorders Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 5.3 Global Genetic Testing For Neurological Disorders Revenue Market Share by Type (2021-2032)
6 Genetic Testing For Neurological Disorders Market Size by Application
  1. 6.1 Global Genetic Testing For Neurological Disorders Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  3. 6.3 Global Genetic Testing For Neurological Disorders Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Illumina
  2. 7.1.1 Illumina Company Information
  3. 7.1.2 Illumina Business Overview
  4. 7.1.3 Illumina Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Illumina Genetic Testing For Neurological Disorders Product Portfolio
  6. 7.1.5 Illumina Recent Developments
  7. 7.2 CENTOGENE
  8. 7.2.1 CENTOGENE Company Information
  9. 7.2.2 CENTOGENE Business Overview
  10. 7.2.3 CENTOGENE Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CENTOGENE Genetic Testing For Neurological Disorders Product Portfolio
  12. 7.2.5 CENTOGENE Recent Developments
  13. 7.3 Victorian Clinical Genetics Services
  14. 7.3.1 Victorian Clinical Genetics Services Company Information
  15. 7.3.2 Victorian Clinical Genetics Services Business Overview
  16. 7.3.3 Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Product Portfolio
  18. 7.3.5 Victorian Clinical Genetics Services Recent Developments
  19. 7.4 PacBio
  20. 7.4.1 PacBio Company Information
  21. 7.4.2 PacBio Business Overview
  22. 7.4.3 PacBio Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  23. 7.4.4 PacBio Genetic Testing For Neurological Disorders Product Portfolio
  24. 7.4.5 PacBio Recent Developments
  25. 7.5 Mayo Clinic
  26. 7.5.1 Mayo Clinic Company Information
  27. 7.5.2 Mayo Clinic Business Overview
  28. 7.5.3 Mayo Clinic Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mayo Clinic Genetic Testing For Neurological Disorders Product Portfolio
  30. 7.5.5 Mayo Clinic Recent Developments
  31. 7.6 Quest Diagnostics
  32. 7.6.1 Quest Diagnostics Company Information
  33. 7.6.2 Quest Diagnostics Business Overview
  34. 7.6.3 Quest Diagnostics Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Quest Diagnostics Genetic Testing For Neurological Disorders Product Portfolio
  36. 7.6.5 Quest Diagnostics Recent Developments
  37. 7.7 MedGenome Labs
  38. 7.7.1 MedGenome Labs Company Information
  39. 7.7.2 MedGenome Labs Business Overview
  40. 7.7.3 MedGenome Labs Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MedGenome Labs Genetic Testing For Neurological Disorders Product Portfolio
  42. 7.7.5 MedGenome Labs Recent Developments
  43. 7.8 GeneDx
  44. 7.8.1 GeneDx Company Information
  45. 7.8.2 GeneDx Business Overview
  46. 7.8.3 GeneDx Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GeneDx Genetic Testing For Neurological Disorders Product Portfolio
  48. 7.8.5 GeneDx Recent Developments
  49. 7.9 Connecticut Children's
  50. 7.9.1 Connecticut Children's Company Information
  51. 7.9.2 Connecticut Children's Business Overview
  52. 7.9.3 Connecticut Children's Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Connecticut Children's Genetic Testing For Neurological Disorders Product Portfolio
  54. 7.9.5 Connecticut Children's Recent Developments
  55. 7.10 Labcorp (Invitae/MNG Laboratories)
  56. 7.10.1 Labcorp (Invitae/MNG Laboratories) Company Information
  57. 7.10.2 Labcorp (Invitae/MNG Laboratories) Business Overview
  58. 7.10.3 Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Product Portfolio
  60. 7.10.5 Labcorp (Invitae/MNG Laboratories) Recent Developments
8 North America
  1. 8.1 North America Genetic Testing For Neurological Disorders Revenue (2021-2032)
  2. 8.2 North America Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 8.2.1 North America Genetic Testing For Neurological Disorders Revenue by Type (2021-2026)
  4. 8.2.2 North America Genetic Testing For Neurological Disorders Revenue by Type (2027-2032)
  5. 8.3 North America Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032)
  6. 8.4 North America Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  7. 8.4.1 North America Genetic Testing For Neurological Disorders Revenue by Application (2021-2026)
  8. 8.4.2 North America Genetic Testing For Neurological Disorders Revenue by Application (2027-2032)
  9. 8.5 North America Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032)
  10. 8.6 North America Genetic Testing For Neurological Disorders Revenue by Country
  11. 8.6.1 North America Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Genetic Testing For Neurological Disorders Revenue by Country (2021-2026)
  13. 8.6.3 North America Genetic Testing For Neurological Disorders Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Genetic Testing For Neurological Disorders Revenue (2021-2032)
  2. 9.2 Europe Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 9.2.1 Europe Genetic Testing For Neurological Disorders Revenue by Type (2021-2026)
  4. 9.2.2 Europe Genetic Testing For Neurological Disorders Revenue by Type (2027-2032)
  5. 9.3 Europe Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032)
  6. 9.4 Europe Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  7. 9.4.1 Europe Genetic Testing For Neurological Disorders Revenue by Application (2021-2026)
  8. 9.4.2 Europe Genetic Testing For Neurological Disorders Revenue by Application (2027-2032)
  9. 9.5 Europe Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032)
  10. 9.6 Europe Genetic Testing For Neurological Disorders Revenue by Country
  11. 9.6.1 Europe Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Genetic Testing For Neurological Disorders Revenue by Country (2021-2026)
  13. 9.6.3 Europe Genetic Testing For Neurological Disorders Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Genetic Testing For Neurological Disorders Revenue (2021-2032)
  2. 10.2 China Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 10.2.1 China Genetic Testing For Neurological Disorders Revenue by Type (2021-2026)
  4. 10.2.2 China Genetic Testing For Neurological Disorders Revenue by Type (2027-2032)
  5. 10.3 China Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032)
  6. 10.4 China Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  7. 10.4.1 China Genetic Testing For Neurological Disorders Revenue by Application (2021-2026)
  8. 10.4.2 China Genetic Testing For Neurological Disorders Revenue by Application (2027-2032)
  9. 10.5 China Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Genetic Testing For Neurological Disorders Revenue (2021-2032)
  2. 11.2 Asia Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 11.2.1 Asia Genetic Testing For Neurological Disorders Revenue by Type (2021-2026)
  4. 11.2.2 Asia Genetic Testing For Neurological Disorders Revenue by Type (2027-2032)
  5. 11.3 Asia Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032)
  6. 11.4 Asia Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  7. 11.4.1 Asia Genetic Testing For Neurological Disorders Revenue by Application (2021-2026)
  8. 11.4.2 Asia Genetic Testing For Neurological Disorders Revenue by Application (2027-2032)
  9. 11.5 Asia Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032)
  10. 11.6 Asia Genetic Testing For Neurological Disorders Revenue by Country
  11. 11.6.1 Asia Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Genetic Testing For Neurological Disorders Revenue by Country (2021-2026)
  13. 11.6.3 Asia Genetic Testing For Neurological Disorders Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Genetic Testing For Neurological Disorders Revenue (2021-2032)
  2. 12.2 SAMEA Genetic Testing For Neurological Disorders Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Genetic Testing For Neurological Disorders Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Genetic Testing For Neurological Disorders Revenue by Type (2027-2032)
  5. 12.3 SAMEA Genetic Testing For Neurological Disorders Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Genetic Testing For Neurological Disorders Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Genetic Testing For Neurological Disorders Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Genetic Testing For Neurological Disorders Revenue by Application (2027-2032)
  9. 12.5 SAMEA Genetic Testing For Neurological Disorders Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Genetic Testing For Neurological Disorders Revenue by Country
  11. 12.6.1 SAMEA Genetic Testing For Neurological Disorders Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Genetic Testing For Neurological Disorders Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Genetic Testing For Neurological Disorders Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst